APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Nivolumab Injection

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Nivolumab Injection Market Outlook and Growth Opportunities 2026

Report ID 17401733042 January 2026199 pages

Choose your research edition.

Industry ResearchNivolumab Injection Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Nivolumab Injection Industry Growth and Trends Forecast to 203290 pages · $3,450 USDMarket StructureGlobal Nivolumab Injection Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032183 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Nivolumab Injection Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Nivolumab Injection Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Nivolumab Injection market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Nivolumab Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Nivolumab Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Nivolumab Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Nivolumab Injection market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Nivolumab Injection market include Sinopharm, AbbVie, Ono Pharmaceutical, Bristol-Myers Squibb and Allergan, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Nivolumab Injection market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Nivolumab Injection and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Nivolumab Injection sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Nivolumab Injection market size, projected growth trends, production technologies, key applications, and end-use industries.

Nivolumab Injection Segment by Company

Sinopharm

AbbVie

Ono Pharmaceutical

Bristol-Myers Squibb

Allergan

Nivolumab Injection Segment by Type

100IU

50IU

Other

Nivolumab Injection Segment by Application

Metastatic Squamous NSCLC

Metastatic Melanoma

Renal Cell Carcinoma

Classical Hodgkin Lymphoma

Unresectable Melanoma

Other

Nivolumab Injection Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Nivolumab Injection status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Nivolumab Injection market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Nivolumab Injection significant trends, drivers, influence factors in global and regions.

6. To analyze Nivolumab Injection competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nivolumab Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Nivolumab Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nivolumab Injection.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Nivolumab Injection market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Nivolumab Injection industry.

Chapter 3: Detailed analysis of Nivolumab Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Nivolumab Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Nivolumab Injection in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Nivolumab Injection Industry Trends Table 2. Nivolumab Injection Industry Drivers Table 3. Nivolumab Injection Industry Opportunities and Challenges Table 4. Nivolumab Injection Industry Restraints Table 5. Global Nivolumab Injection Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Nivolumab Injection Revenue Share by Company (2021-2026) Table 7. Global Nivolumab Injection Sales Volume by Company (Units) & (2021-2026) Table 8. Global Nivolumab Injection Sales Volume Share by Company (2021-2026) Table 9. Global Nivolumab Injection Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Nivolumab Injection Company Ranking, (2024-2026) & (USD Million) Table 11. Global Nivolumab Injection Key Company Manufacturing Base & Headquarters Table 12. Global Nivolumab Injection Company, Product Type & Application Table 13. Global Nivolumab Injection Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Nivolumab Injection by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of 100IU Table 18. Significant Companies of 50IU Table 19. Significant Companies of Other Table 20. Global Nivolumab Injection Sales Volume by Type 2021 VS 2025 VS 2032 (Units) Table 21. Global Nivolumab Injection Sales Volume by Type (2021-2026) & (Units) Table 22. Global Nivolumab Injection Sales Volume by Type (2027-2032) & (Units) Table 23. Global Nivolumab Injection Sales Volume Share by Type (2021-2026) Table 24. Global Nivolumab Injection Sales Volume Share by Type (2027-2032) Table 25. Global Nivolumab Injection Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Nivolumab Injection Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Nivolumab Injection Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Nivolumab Injection Sales Value Share by Type (2021-2026) Table 29. Global Nivolumab Injection Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Metastatic Squamous NSCLC Table 31. Significant Companies of Metastatic Melanoma Table 32. Significant Companies of Renal Cell Carcinoma Table 33. Significant Companies of Classical Hodgkin Lymphoma Table 34. Significant Companies of Unresectable Melanoma Table 35. Significant Companies of Other Table 36. Global Nivolumab Injection Sales Volume by Application 2021 VS 2025 VS 2032 (Units) Table 37. Global Nivolumab Injection Sales Volume by Application (2021-2026) & (Units) Table 38. Global Nivolumab Injection Sales Volume by Application (2027-2032) & (Units) Table 39. Global Nivolumab Injection Sales Volume Share by Application (2021-2026) Table 40. Global Nivolumab Injection Sales Volume Share by Application (2027-2032) Table 41. Global Nivolumab Injection Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 42. Global Nivolumab Injection Sales Value by Application (2021-2026) & (US$ Million) Table 43. Global Nivolumab Injection Sales Value by Application (2027-2032) & (US$ Million) Table 44. Global Nivolumab Injection Sales Value Share by Application (2021-2026) Table 45. Global Nivolumab Injection Sales Value Share by Application (2027-2032) Table 46. Global Nivolumab Injection Sales by Region: 2021 VS 2025 VS 2032 (Units) Table 47. Global Nivolumab Injection Sales by Region (2021-2026) & (Units) Table 48. Global Nivolumab Injection Sales Market Share by Region (2021-2026) Table 49. Global Nivolumab Injection Sales by Region (2027-2032) & (Units) Table 50. Global Nivolumab Injection Sales Market Share by Region (2027-2032) Table 51. Global Nivolumab Injection Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 52. Global Nivolumab Injection Sales Value by Region (2021-2026) & (US$ Million) Table 53. Global Nivolumab Injection Sales Value Share by Region (2021-2026) Table 54. Global Nivolumab Injection Sales Value by Region (2027-2032) & (US$ Million) Table 55. Global Nivolumab Injection Sales Value Share by Region (2027-2032) Table 56. Global Nivolumab Injection Market Average Price (US$/Unit) by Region (2021-2026) Table 57. Global Nivolumab Injection Market Average Price (US$/Unit) by Region (2027-2032) Table 58. Global Nivolumab Injection Sales by Country: 2021 VS 2025 VS 2032 (Units) Table 59. Global Nivolumab Injection Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Nivolumab Injection Sales by Country (2021-2026) & (Units) Table 61. Global Nivolumab Injection Sales Market Share by Country (2021-2026) Table 62. Global Nivolumab Injection Sales by Country (2027-2032) & (Units) Table 63. Global Nivolumab Injection Sales Market Share by Country (2027-2032) Table 64. Global Nivolumab Injection Sales Value by Country (2021-2026) & (US$ Million) Table 65. Global Nivolumab Injection Sales Value Market Share by Country (2021-2026) Table 66. Global Nivolumab Injection Sales Value by Country (2027-2032) & (US$ Million) Table 67. Global Nivolumab Injection Sales Value Market Share by Country (2027-2032) Table 68. Sinopharm Company Information Table 69. Sinopharm Business Overview Table 70. Sinopharm Nivolumab Injection Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Sinopharm Nivolumab Injection Product Portfolio Table 72. Sinopharm Recent Development Table 73. AbbVie Company Information Table 74. AbbVie Business Overview Table 75. AbbVie Nivolumab Injection Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. AbbVie Nivolumab Injection Product Portfolio Table 77. AbbVie Recent Development Table 78. Ono Pharmaceutical Company Information Table 79. Ono Pharmaceutical Business Overview Table 80. Ono Pharmaceutical Nivolumab Injection Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Ono Pharmaceutical Nivolumab Injection Product Portfolio Table 82. Ono Pharmaceutical Recent Development Table 83. Bristol-Myers Squibb Company Information Table 84. Bristol-Myers Squibb Business Overview Table 85. Bristol-Myers Squibb Nivolumab Injection Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Bristol-Myers Squibb Nivolumab Injection Product Portfolio Table 87. Bristol-Myers Squibb Recent Development Table 88. Allergan Company Information Table 89. Allergan Business Overview Table 90. Allergan Nivolumab Injection Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Allergan Nivolumab Injection Product Portfolio Table 92. Allergan Recent Development Table 93. Key Raw Materials Table 94. Raw Materials Key Suppliers Table 95. Nivolumab Injection Distributors List Table 96. Nivolumab Injection Customers List Table 97. Research Programs/Design for This Report Table 98. Authors List of This Report Table 99. Secondary Sources Table 100. Primary Sources List of Figures Figure 1. Nivolumab Injection Product Image Figure 2. Global Nivolumab Injection Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Nivolumab Injection Sales Value (2021-2032) & (US$ Million) Figure 4. Global Nivolumab Injection Sales (2021-2032) & (Units) Figure 5. Global Nivolumab Injection Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Nivolumab Injection Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. 100IU Image Figure 10. 50IU Image Figure 11. Other Image Figure 12. Global Nivolumab Injection Sales Volume by Type (2021 VS 2025 VS 2032) & (Units) Figure 13. Global Nivolumab Injection Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Nivolumab Injection Sales Volume Share by Type (2021-2032) Figure 15. Global Nivolumab Injection Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Nivolumab Injection Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Nivolumab Injection Sales Value Share by Type (2021-2032) Figure 18. Metastatic Squamous NSCLC Image Figure 19. Metastatic Melanoma Image Figure 20. Renal Cell Carcinoma Image Figure 21. Classical Hodgkin Lymphoma Image Figure 22. Unresectable Melanoma Image Figure 23. Other Image Figure 24. Global Nivolumab Injection Sales Volume by Application (2021 VS 2025 VS 2032) & (Units) Figure 25. Global Nivolumab Injection Sales Volume Share 2021 VS 2025 VS 2032 Figure 26. Global Nivolumab Injection Sales Volume Share by Application (2021-2032) Figure 27. Global Nivolumab Injection Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Nivolumab Injection Sales Value Share 2021 VS 2025 VS 2032 Figure 29. Global Nivolumab Injection Sales Value Share by Application (2021-2032) Figure 30. Global Nivolumab Injection Sales by Region: 2021 VS 2025 VS 2032 (Units) Figure 31. Global Nivolumab Injection Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 32. Global Nivolumab Injection Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 33. Global Nivolumab Injection Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 34. North America Nivolumab Injection Sales Value (2021-2032) & (US$ Million) Figure 35. North America Nivolumab Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Europe Nivolumab Injection Sales Value (2021-2032) & (US$ Million) Figure 37. Europe Nivolumab Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Asia-Pacific Nivolumab Injection Sales Value (2021-2032) & (US$ Million) Figure 39. Asia-Pacific Nivolumab Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 40. South America Nivolumab Injection Sales Value (2021-2032) & (US$ Million) Figure 41. South America Nivolumab Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 42. Middle East & Africa Nivolumab Injection Sales Value (2021-2032) & (US$ Million) Figure 43. Middle East & Africa Nivolumab Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 44. USA Nivolumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. USA Nivolumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. USA Nivolumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Canada Nivolumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Canada Nivolumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Canada Nivolumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Mexico Nivolumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Mexico Nivolumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Mexico Nivolumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Germany Nivolumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Germany Nivolumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Germany Nivolumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. France Nivolumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. France Nivolumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. France Nivolumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. U.K. Nivolumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. U.K. Nivolumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. U.K. Nivolumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Italy Nivolumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Italy Nivolumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Italy Nivolumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Spain Nivolumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Spain Nivolumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Spain Nivolumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Russia Nivolumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Russia Nivolumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Russia Nivolumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Netherlands Nivolumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Netherlands Nivolumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Netherlands Nivolumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Nordic Countries Nivolumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Nordic Countries Nivolumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Nordic Countries Nivolumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. China Nivolumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. China Nivolumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. China Nivolumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Japan Nivolumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Japan Nivolumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Japan Nivolumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. South Korea Nivolumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. South Korea Nivolumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. South Korea Nivolumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. India Nivolumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. India Nivolumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. India Nivolumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Australia Nivolumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Australia Nivolumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Australia Nivolumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Southeast Asia Nivolumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Southeast Asia Nivolumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Southeast Asia Nivolumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Brazil Nivolumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Brazil Nivolumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Brazil Nivolumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Argentina Nivolumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Argentina Nivolumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Argentina Nivolumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Chile Nivolumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Chile Nivolumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Chile Nivolumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Colombia Nivolumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Colombia Nivolumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Colombia Nivolumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Peru Nivolumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Peru Nivolumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Peru Nivolumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Nivolumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Saudi Arabia Nivolumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Saudi Arabia Nivolumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Israel Nivolumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Israel Arabia Nivolumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Israel Arabia Nivolumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. UAE Nivolumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. UAE Nivolumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. UAE Nivolumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Turkey Nivolumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Turkey Nivolumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Turkey Nivolumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Iran Nivolumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Iran Nivolumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Iran Nivolumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Egypt Nivolumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 126. Egypt Nivolumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 127. Egypt Nivolumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 128. Nivolumab Injection Value Chain Figure 129. Manufacturing Cost Structure Figure 130. Nivolumab Injection Sales Mode & Process Figure 131. Direct Comparison with Distribution Share Figure 132. Distributors Profiles Figure 133. Years Considered Figure 134. Research Process Figure 135. Key Executives Interviewed

Scope & coverage.

Types
  • 100IU
  • 50IU
  • Other
Applications
  • Metastatic Squamous NSCLC
  • Metastatic Melanoma
  • Renal Cell Carcinoma
  • Classical Hodgkin Lymphoma
  • Unresectable Melanoma
  • Other
Companies covered
  • Sinopharm
  • AbbVie
  • Ono Pharmaceutical
  • Bristol-Myers Squibb
  • Allergan

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Nivolumab Injection Sales Value (2021-2032)
  4. 1.2.2 Global Nivolumab Injection Sales Volume (2021-2032)
  5. 1.2.3 Global Nivolumab Injection Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Nivolumab Injection Market Dynamics
  1. 2.1 Nivolumab Injection Industry Trends
  2. 2.2 Nivolumab Injection Industry Drivers
  3. 2.3 Nivolumab Injection Industry Opportunities and Challenges
  4. 2.4 Nivolumab Injection Industry Restraints
3 Nivolumab Injection Market by Company
  1. 3.1 Global Nivolumab Injection Company Revenue Ranking in 2025
  2. 3.2 Global Nivolumab Injection Revenue by Company (2021-2026)
  3. 3.3 Global Nivolumab Injection Sales Volume by Company (2021-2026)
  4. 3.4 Global Nivolumab Injection Average Price by Company (2021-2026)
  5. 3.5 Global Nivolumab Injection Company Ranking (2024-2026)
  6. 3.6 Global Nivolumab Injection Company Manufacturing Base and Headquarters
  7. 3.7 Global Nivolumab Injection Company Product Type and Application
  8. 3.8 Global Nivolumab Injection Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Nivolumab Injection Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Nivolumab Injection Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Nivolumab Injection Market by Type
  1. 4.1 Nivolumab Injection Type Introduction
  2. 4.1.1 100IU
  3. 4.1.2 50IU
  4. 4.1.3 Other
  5. 4.2 Global Nivolumab Injection Sales Volume by Type
  6. 4.2.1 Global Nivolumab Injection Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Nivolumab Injection Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Nivolumab Injection Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Nivolumab Injection Sales Value by Type
  10. 4.3.1 Global Nivolumab Injection Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Nivolumab Injection Sales Value by Type (2021-2032)
  12. 4.3.3 Global Nivolumab Injection Sales Value Share by Type (2021-2032)
5 Nivolumab Injection Market by Application
  1. 5.1 Nivolumab Injection Application Introduction
  2. 5.1.1 Metastatic Squamous NSCLC
  3. 5.1.2 Metastatic Melanoma
  4. 5.1.3 Renal Cell Carcinoma
  5. 5.1.4 Classical Hodgkin Lymphoma
  6. 5.1.5 Unresectable Melanoma
  7. 5.1.6 Other
  8. 5.2 Global Nivolumab Injection Sales Volume by Application
  9. 5.2.1 Global Nivolumab Injection Sales Volume by Application (2021 VS 2025 VS 2032)
  10. 5.2.2 Global Nivolumab Injection Sales Volume by Application (2021-2032)
  11. 5.2.3 Global Nivolumab Injection Sales Volume Share by Application (2021-2032)
  12. 5.3 Global Nivolumab Injection Sales Value by Application
  13. 5.3.1 Global Nivolumab Injection Sales Value by Application (2021 VS 2025 VS 2032)
  14. 5.3.2 Global Nivolumab Injection Sales Value by Application (2021-2032)
  15. 5.3.3 Global Nivolumab Injection Sales Value Share by Application (2021-2032)
6 Nivolumab Injection Regional Sales and Value Analysis
  1. 6.1 Global Nivolumab Injection Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Nivolumab Injection Sales by Region (2021-2032)
  3. 6.2.1 Global Nivolumab Injection Sales by Region: 2021-2026
  4. 6.2.2 Global Nivolumab Injection Sales by Region (2027-2032)
  5. 6.3 Global Nivolumab Injection Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Nivolumab Injection Sales Value by Region (2021-2032)
  7. 6.4.1 Global Nivolumab Injection Sales Value by Region: 2021-2026
  8. 6.4.2 Global Nivolumab Injection Sales Value by Region (2027-2032)
  9. 6.5 Global Nivolumab Injection Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Nivolumab Injection Sales Value (2021-2032)
  12. 6.6.2 North America Nivolumab Injection Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Nivolumab Injection Sales Value (2021-2032)
  15. 6.7.2 Europe Nivolumab Injection Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Nivolumab Injection Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Nivolumab Injection Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Nivolumab Injection Sales Value (2021-2032)
  21. 6.9.2 South America Nivolumab Injection Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Nivolumab Injection Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Nivolumab Injection Sales Value Share by Country, 2025 VS 2032
7 Nivolumab Injection Country-level Sales and Value Analysis
  1. 7.1 Global Nivolumab Injection Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Nivolumab Injection Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Nivolumab Injection Sales by Country (2021-2032)
  4. 7.3.1 Global Nivolumab Injection Sales by Country (2021-2026)
  5. 7.3.2 Global Nivolumab Injection Sales by Country (2027-2032)
  6. 7.4 Global Nivolumab Injection Sales Value by Country (2021-2032)
  7. 7.4.1 Global Nivolumab Injection Sales Value by Country (2021-2026)
  8. 7.4.2 Global Nivolumab Injection Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Nivolumab Injection Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Nivolumab Injection Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Nivolumab Injection Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Nivolumab Injection Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Nivolumab Injection Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Nivolumab Injection Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Nivolumab Injection Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Nivolumab Injection Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Nivolumab Injection Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Nivolumab Injection Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Nivolumab Injection Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Nivolumab Injection Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Nivolumab Injection Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Nivolumab Injection Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Nivolumab Injection Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Nivolumab Injection Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Nivolumab Injection Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Nivolumab Injection Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Nivolumab Injection Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Nivolumab Injection Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Nivolumab Injection Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Nivolumab Injection Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Nivolumab Injection Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Nivolumab Injection Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Nivolumab Injection Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Nivolumab Injection Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Nivolumab Injection Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Nivolumab Injection Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Nivolumab Injection Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Nivolumab Injection Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Nivolumab Injection Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Nivolumab Injection Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Nivolumab Injection Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Nivolumab Injection Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Nivolumab Injection Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Nivolumab Injection Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Nivolumab Injection Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Nivolumab Injection Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Nivolumab Injection Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Nivolumab Injection Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Nivolumab Injection Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Nivolumab Injection Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Nivolumab Injection Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Nivolumab Injection Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Nivolumab Injection Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Nivolumab Injection Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Nivolumab Injection Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Nivolumab Injection Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Nivolumab Injection Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Nivolumab Injection Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Nivolumab Injection Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Nivolumab Injection Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Nivolumab Injection Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Nivolumab Injection Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Nivolumab Injection Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Nivolumab Injection Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Nivolumab Injection Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Nivolumab Injection Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Nivolumab Injection Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Nivolumab Injection Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Nivolumab Injection Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Nivolumab Injection Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Nivolumab Injection Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Nivolumab Injection Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Nivolumab Injection Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Nivolumab Injection Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Nivolumab Injection Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Nivolumab Injection Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Nivolumab Injection Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Nivolumab Injection Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Nivolumab Injection Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Nivolumab Injection Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Nivolumab Injection Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Nivolumab Injection Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Nivolumab Injection Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Nivolumab Injection Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Nivolumab Injection Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Nivolumab Injection Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Nivolumab Injection Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Nivolumab Injection Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Nivolumab Injection Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Nivolumab Injection Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Nivolumab Injection Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Nivolumab Injection Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sinopharm
  2. 8.1.1 Sinopharm Company Information
  3. 8.1.2 Sinopharm Business Overview
  4. 8.1.3 Sinopharm Nivolumab Injection Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Sinopharm Nivolumab Injection Product Portfolio
  6. 8.1.5 Sinopharm Recent Developments
  7. 8.2 AbbVie
  8. 8.2.1 AbbVie Company Information
  9. 8.2.2 AbbVie Business Overview
  10. 8.2.3 AbbVie Nivolumab Injection Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 AbbVie Nivolumab Injection Product Portfolio
  12. 8.2.5 AbbVie Recent Developments
  13. 8.3 Ono Pharmaceutical
  14. 8.3.1 Ono Pharmaceutical Company Information
  15. 8.3.2 Ono Pharmaceutical Business Overview
  16. 8.3.3 Ono Pharmaceutical Nivolumab Injection Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Ono Pharmaceutical Nivolumab Injection Product Portfolio
  18. 8.3.5 Ono Pharmaceutical Recent Developments
  19. 8.4 Bristol-Myers Squibb
  20. 8.4.1 Bristol-Myers Squibb Company Information
  21. 8.4.2 Bristol-Myers Squibb Business Overview
  22. 8.4.3 Bristol-Myers Squibb Nivolumab Injection Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Bristol-Myers Squibb Nivolumab Injection Product Portfolio
  24. 8.4.5 Bristol-Myers Squibb Recent Developments
  25. 8.5 Allergan
  26. 8.5.1 Allergan Company Information
  27. 8.5.2 Allergan Business Overview
  28. 8.5.3 Allergan Nivolumab Injection Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Allergan Nivolumab Injection Product Portfolio
  30. 8.5.5 Allergan Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Nivolumab Injection Value Chain Analysis
  2. 9.1.1 Nivolumab Injection Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Nivolumab Injection Sales Mode & Process
  6. 9.2 Nivolumab Injection Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Nivolumab Injection Distributors
  9. 9.2.3 Nivolumab Injection Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst